OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a Chinese Contract Research Organization (CRO) specializing in gene therapy, has entered into a strategic partnership with Shanghai Saierxin Biomedical Technology Co., Ltd. Under the terms of the agreement, OBiO will offer non-registered clinical trial sample preparation and testing services for Saierxin Bio’s Treg cell therapy pipeline, NP001. Additionally, OBiO will provide IND declaration CMC services and clinical sample production services for both the NP001 and NC001 projects.
Saierxin Bio, a company dedicated to the development of Treg cell therapies for the treatment of neurodegenerative diseases, autoimmune diseases, and metabolic diseases, has completed the process development and confirmation of its NP001 program. Ethical filing for this program has been made in China, with the intention to treat amyotrophic lateral sclerosis (ALS). The collaboration with OBiO Technology is expected to bolster Saierxin Bio’s efforts in advancing its therapeutic pipeline.- Flcube.com
